Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ANPEP | P15144 | 1/20 | 0.45 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.33 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.33 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL472195 | 1.00 | MAPT (0.49) | MAPTANPEPERAP2CHRM5CHRM3 | |
| SCHEMBL336756 | 0.98 | MAPT (0.50) | MAPTANPEPERAP2CHRM5CHRM3 | |
| SCHEMBL7453394 | 0.98 | MAPT (0.50) | MAPTANPEPERAP2CHRM5CHRM3 | |
| SCHEMBL8393831 | 0.95 | MAPT (0.49) | MAPTANPEPERAP2CHRM5CHRM3 | |
| SCHEMBL9041381 | 0.95 | MAPT (0.49) | MAPTANPEPERAP2CHRM5CHRM3 | |
| Hydrochloric Acid SCHEMBL31341457 | 0.95 | MAPT (0.49) | MAPTANPEPERAP2CHRM5CHRM3 | |
| SCHEMBL13805262 | 0.90 | CXCR4 (0.44) | MAPTANPEPERAP2CHRM5CHRM3 | |
| SCHEMBL13805263 | 0.90 | CXCR4 (0.47) | MAPTANPEPERAP2CHRM5CHRM3 | |
| SCHEMBL16800520 | 0.87 | MAPT (0.47) | MAPTANPEPERAP2CHRM5CHRM3 | |
| SCHEMBL30811210 | 0.87 | MAPT (0.47) | MAPTANPEPERAP2CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021116712-A1 | FUNCTIONALISED MICROBUBBLE MEDIATED CELL TAGGING | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-06-17 | — | — | WO | claimed |
| US-10874753-B2 | Radiopharmaceutical conjugate of a metabolite and an EPR agent, for targeting tumour cells | THE SOUTH AFRICAN NUCLEAR ENERGY CORPORATION LIMITED (ZA) | 2020-12-29 | — | — | US | claimed |
| EP-3703676-A1 | COMPOSITION AND METHOD FOR MODIFYING POLYPEPTIDES | Advanced Proteome Therapeutics, Inc. (US) | 2020-09-09 | — | — | EP | claimed |
| US-20190175750-A1 | COMPOSITION AND METHOD FOR MODIFYING POLYPEPTIDES | ADVANCED PROTEOME THERAPEUTICS INC. | 2019-06-13 | — | — | US | claimed |
| EP-2453927-B1 | LOADING TECHNIQUE FOR PREPARING RADIONUCLIDE AND IONOPHORE CONTAINING LIPOSOMES IN WHICH THE IONOPHORE IS 2-HYDROXYQUIONOLINE (CARBOSTYRIL) OR STRUCTURALLY RELATED 2-HYDROXYQUINOLINES | UNIV DENMARK TECH DTU (DK) | 2019-05-15 | — | — | EP | claimed |
| EP-2651447-B1 | ENTRAPMENT OF RADIONUCLIDES IN NANOPARTICLE COMPOSITIONS | UNIV DENMARK TECH DTU (DK) | 2018-08-29 | — | — | EP | claimed |
| US-20170296684-A1 | RADIOPHARMACEUTICAL CONJUGATE | UNIVERSITY OF CAPE TOWN (ZA) | 2017-10-19 | — | — | US | claimed |
| US-20160158392-A1 | Entrapment of Radionuclides in Nanoparticle Compositions | RIGSHOSPITALET (DK) | 2016-06-09 | — | — | US | claimed |
| US-9226984-B2 | Entrapment of radionuclides in nanoparticle compositions | Technical University of Denmark and Rigshospitalet (DK) | 2016-01-05 | — | — | US | claimed |
| US-8920775-B2 | Loading technique for preparing radionuclide containing nanoparticles | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2014-12-30 | — | — | US | claimed |
| US-20130251630-A1 | Entrapment of Radionuclides in Nanoparticle Compositions | RIGSHOSPITALET (DK) | 2013-09-26 | — | — | US | claimed |
| US-20120213698-A1 | LOADING TECHNIQUE FOR PREPARING RADIONUCLIDE CONTAINING NANOPARTICLES | RIGSHOSPITALET (DK) | 2012-08-23 | — | — | US | claimed |
| EP-2399938-A2 | Peptide purification by means of hard metal ion affinity chromatography | Novo Nordisk A/S (DK) | 2011-12-28 | — | — | EP | claimed |
| EP-4610269-A1 | UROKINASE PLASMINOGEN ACTIVATOR SURFACE RECEPTOR (UPAR) LIGANDS FOR DIAGNOSTIC OR THERAPEUTIC USE | 3B Pharmaceuticals GmbH (DE) | 2025-09-03 | — | — | EP | disclosed |
| EP-4583917-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B Pharmaceuticals GmbH (DE) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024052431-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2024-03-14 | — | — | WO | disclosed |
| US-20090143529-A1 | Peptide purification by means of hard metal ion affinity chromatography | HEARN MILTON THOMAS WILLIAM | 2009-06-04 | — | — | US | disclosed |
| US-20090143529-A1 | Peptide purification by means of hard metal ion affinity chromatography | HEARN MILTON THOMAS WILLIAM | 2009-06-04 | — | — | US | disclosed |
| US-20070048216-A1 | Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-03-01 | — | — | US | disclosed |
| US-20070025910-A1 | Anticancer therapy | REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874753-B2 | Radiopharmaceutical conjugate of a metabolite and an EPR agent, for targeting tumour cells | EPRS1, FOLH1, SLC46A1 | MAPT 3477/4885ANPEP 156/4885ERAP2 445/4885 |
| US-20070048216-A1 | Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma | MCL1, BCL3, BCL9 | MAPT 4381/4885ANPEP 1531/4885ERAP2 3178/4885 |
| US-20090143529-A1 | Peptide purification by means of hard metal ion affinity chromatography | MAX, PTMS, SLC7A1 | MAPT 2874/4885ANPEP 7/4885ERAP2 2195/4885 |
| US-20190175750-A1 | COMPOSITION AND METHOD FOR MODIFYING POLYPEPTIDES | PTMS, SRMS, ACP1 | MAPT 592/4885ANPEP 161/4885ERAP2 1595/4885 |
| US-20120213698-A1 | LOADING TECHNIQUE FOR PREPARING RADIONUCLIDE CONTAINING NANOPARTICLES | LIPG, NPC1L1, CD47 | MAPT 4367/4885ANPEP 731/4885ERAP2 1034/4885 |
| US-20170296684-A1 | RADIOPHARMACEUTICAL CONJUGATE | FOLH1, EPRS1, FOLR1 | MAPT 3460/4885ANPEP 122/4885ERAP2 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.